Sai Parenteral’s IPO 2026: Date, Price Band ₹372–₹392, GMP & Allotment

By /
Sai Parenteral's IPO
SP
Sai Parenteral’s Limited IPO
Pharmaceutical Formulations · CDMO · Branded Generics · Injectables
📋 Mainline IPO Fresh + OFS NSE, BSE
₹392
Upper Price
₹408.79 Cr
Issue Size
Apr 2, 2026
Listing Date
₹1,731.83 Cr
Market Cap (Pre)
📅 IPO Timetable
Tentative dates
🟢
IPO Opens
Tuesday, 24 March 2026
Bidding starts — apply before close
🔒
IPO Closes
Friday, 27 March 2026
Last day to bid — closes at 5:00 PM IST
📊
Basis of Allotment
Monday, 30 March 2026
Allotment finalised by registrar
🔄
Refund & Share Credit
Wednesday, 1 April 2026
Unallotted funds returned; shares credited to demat
🏷️
Thursday, 2 April 2026
Trading begins on BSE & NSE at 10:00 AM IST
📋 IPO Details
Key issue information
IPO Open Date24 March 2026 (Tue)
IPO Close Date27 March 2026 (Fri)
Listing Date2 April 2026 (Thu)
Face Value₹5 per share
Price Band₹372 to ₹392
Issue Price (Upper)₹392 per share
Issue TypeBook Build — Fresh + OFS
Lot Size38 shares
Total Issue Size1,04,28,288 shares (₹408.79 Cr)
Fresh Issue72,70,408 shares (₹285 Cr)
Offer for Sale (OFS)31,57,880 shares (₹123.79 Cr)
Listing AtBSE, NSE
Pre-Issue Shares3,69,08,823
Post-Issue Shares4,41,79,231
Promoter Holding (Pre)61.23%
Market Cap (Pre-IPO)₹1,731.83 Cr
Lead ManagerArihant Capital Markets Ltd.
RegistrarBigshare Services Pvt.Ltd.
💰 Lot Size & Minimum Investment
At upper price ₹392
Investor TypeLotsSharesAmount
Retail — Minimum138₹14,896
Retail — Maximum13494₹1,93,648
S-HNI (sNII) — Min14532₹2,08,544
S-HNI (sNII) — Max672,546₹9,98,032
B-HNI (bNII) — Min682,584₹10,12,928
⚠️ Note: Investors can bid for a minimum of 38 shares and in multiples thereof. Retail individual investors can apply up to ₹2,00,000.
👥 Investor Reservation
Allocated portion
Not more than 50%
QIB Portion
Net Offer Shares
Not less than 35%
Retail Portion
Net Offer Shares
Not less than 15%
NII (HNI) Portion
Net Offer Shares
📈 Company Financials
Restated Consolidated · ₹ Crore
Metric30 Sep 202531 Mar 202531 Mar 202431 Mar 2023
Total Assets376.24272.39268.10133.96
Total Income89.43163.74155.1897.03
PAT7.7614.438.424.38
EBITDA16.2439.4431.7017.64
Net Worth209.3795.7876.4031.49
Total Borrowings76.0793.95118.7968.55
📊 Key Performance Indicators
16.82%
ROE
FY 2024–25
28.92%
ROCE
FY 2024–25
8.88%
PAT Margin
FY 2024–25
24.18%
EBITDA Margin
FY 2024–25
5.13%
ROE (H1)
Sep 30, 2025
10.89x
Price/Book
Sep 30, 2025
💹 Valuation & EPS
Pre-IPO EPS
₹5.43
Based on Mar 31, 2025 Earnings
P/E: 72.19x
Market Cap (Pre-IPO)
₹1,731.83 Cr
At upper price ₹392
ℹ️ Pre-IPO EPS is calculated based on Pre-issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2025. Post-Issue EPS is based on post-issue shares and annualised H1 FY26 earnings.
🎯 Objects of the Issue
Net proceeds utilisation
Capacity expansion and upgradation of manufacturing facilities
₹110.80 Cr
Investment in Singapore subsidiary for proposed acquisition in Australia
₹35.64 Cr
Working capital requirements
₹33.00 Cr
Establishment of a new R&D Centre
₹18.02 Cr
Repayment / prepayment of certain outstanding borrowings
₹14.30 Cr
Total (Core Objects) ₹211.76 Cr
🏢 About Sai Parenteral’s Limited
Est. 2001 · Hyderabad · Pharmaceuticals

Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company specializing in Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) services. Its therapeutic portfolio includes cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, and antibiotics across dosage forms like injectables, tablets, and capsules.

The company operates five manufacturing facilities (four in Hyderabad and one in Ongole). Notable facilities include TGA-Australia and PIC/S accredited solid oral dosage units. It serves government agencies, major hospitals, and international markets including Australia, Southeast Asia, and the Middle East. As of Dec 31, 2025, the company has 298 full-time employees.

Therapeutic Areas
💊
Chronic Care
Cardiovascular, Neuropsychiatry, Anti-Diabetic, Respiratory health
🔬
Acute Care
Antibiotics, Gastroenterology, Analgesics, and Dermatology
💉
Dosage Forms
Injectables, Tablets, Capsules, Liquid Orals, and Ointments
🌍
Segments
Branded Generic Formulations and CDMO products/services
Competitive Strengths
✅Diversified generic formulations player with established track record
🏭Strategically located and accredited (WHO-GMP, TGA-Australia) Manufacturing Facilities
🔬Strong focus on high-growth CDMO business model
📈Track record of value-accretive acquisitions and international expansion
Company Promoters
AK
Anil Kumar Karusala
Promoter, Sai Parenteral’s Limited
VG
Vijitha Gorrepati
Promoter, Sai Parenteral’s Limited
📅 Key Dates
IPO Opens24 Mar 2026
IPO Closes27 Mar 2026
Allotment30 Mar 2026
Refund & Credit1 Apr 2026
Listing Day2 Apr 2026
💡 Quick Summary
Price Band₹372 – ₹392
Upper Price₹392 / share
Lot Size38 shares
Min. Investment₹14,896
Issue Size₹408.79 Cr
Fresh Issue₹285.00 Cr
ListingBSE, NSE
🏦 Registrar & Lead Manager
Registrar
Bigshare Services Pvt.Ltd.
📞 +91-22-6263 8200
ipo@bigshareonline.com
Lead Manager
Arihant Capital Markets Ltd.
📍 Registered Address
Sai Parenteral’s Ltd.
Plot No 39, 5th floor, Lavanya Arcade,
Jayabheri Enclave, Gachibowli,
Hyderabad, Telangana — 500032
📞 +91 79979 91301
cs@saiparenterals.com
🛡️ Regulatory Note: Mainline IPO investments are subject to SEBI regulations. This issue lists on both BSE and NSE. Always read the RHP before applying.
⚠️ Disclaimer: This page presents publicly available information from the Sai Parenteral IPO RHP for informational purposes only. It does not constitute investment advice. IPO investments are subject to market risk. Please read all offer documents and consult a SEBI-registered advisor before investing.
📊
Track Sai Parenteral’s IPO 2026: Date, Price Band ₹372–₹392, GMP & Allotment GMP
Check real-time grey market premium, daily GMP history & estimated listing price.
Check GMP →

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top